SE0202365D0 - New formulation and use thereof - Google Patents

New formulation and use thereof

Info

Publication number
SE0202365D0
SE0202365D0 SE0202365A SE0202365A SE0202365D0 SE 0202365 D0 SE0202365 D0 SE 0202365D0 SE 0202365 A SE0202365 A SE 0202365A SE 0202365 A SE0202365 A SE 0202365A SE 0202365 D0 SE0202365 D0 SE 0202365D0
Authority
SE
Sweden
Prior art keywords
new formulation
composition
sexual
dysfunction
compound
Prior art date
Application number
SE0202365A
Other languages
Swedish (sv)
Inventor
Nils-Olof Lindberg
Katarina Lindell
Kristina Thyresson
Alice C Martino
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE0202365A priority Critical patent/SE0202365D0/en
Publication of SE0202365D0 publication Critical patent/SE0202365D0/en
Priority to EP03733755A priority patent/EP1539096A1/en
Priority to AU2003239038A priority patent/AU2003239038B2/en
Priority to JP2004525901A priority patent/JP2005539008A/en
Priority to BR0313224-2A priority patent/BR0313224A/en
Priority to MXPA05000978A priority patent/MXPA05000978A/en
Priority to PCT/SE2003/001022 priority patent/WO2004012702A1/en
Priority to NZ537520A priority patent/NZ537520A/en
Priority to CN038188910A priority patent/CN1674866B/en
Priority to RU2005102835/15A priority patent/RU2312665C2/en
Priority to CA002495527A priority patent/CA2495527C/en
Priority to TW092120418A priority patent/TW200418470A/en
Priority to AR20030102814A priority patent/AR040797A1/en
Priority to US10/634,159 priority patent/US20040126448A1/en
Priority to IL16603104A priority patent/IL166031A0/en
Priority to ZA2005/00051A priority patent/ZA200500051B/en
Priority to US11/561,650 priority patent/US20070092554A1/en
Priority to US12/623,723 priority patent/US20100069397A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Abstract

A sexual-dysfunction-compound-containing rapid-onset pharmaceutical composition that comprises cocoa powder, process for manufacturing the composition and use of the composition in sexual dysfunction therapy.
SE0202365A 2002-08-05 2002-08-05 New formulation and use thereof SE0202365D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE0202365A SE0202365D0 (en) 2002-08-05 2002-08-05 New formulation and use thereof
AU2003239038A AU2003239038B2 (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
CN038188910A CN1674866B (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
CA002495527A CA2495527C (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
JP2004525901A JP2005539008A (en) 2002-08-05 2003-06-18 New pharmaceutical preparation containing a compound for sexual dysfunction including cacao powder and rapid onset of action and use thereof
BR0313224-2A BR0313224A (en) 2002-08-05 2003-06-18 Pharmaceutical composition containing orally administered sexual dysfunction therapy compound which provides rapid onset of its pharmacological effects
MXPA05000978A MXPA05000978A (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof.
PCT/SE2003/001022 WO2004012702A1 (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
NZ537520A NZ537520A (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
EP03733755A EP1539096A1 (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
RU2005102835/15A RU2312665C2 (en) 2002-08-05 2003-06-18 Novel rapidly acting pharmaceutical compositions containing compounds eliciting activity in sexual dysfunction and cacao powder and their using
TW092120418A TW200418470A (en) 2002-08-05 2003-07-25 New formulations and use thereof
US10/634,159 US20040126448A1 (en) 2002-08-05 2003-08-05 Sexual dysfunction compounds
AR20030102814A AR040797A1 (en) 2002-08-05 2003-08-05 FORMULATIONS FOR SEXUAL DYSFUNCTION AND USES OF THE SAME
IL16603104A IL166031A0 (en) 2002-08-05 2004-12-28 New sexual-dysfunction-compound containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
ZA2005/00051A ZA200500051B (en) 2002-08-05 2005-01-04 New sexual-dysfuction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
US11/561,650 US20070092554A1 (en) 2002-08-05 2006-11-20 Sexual Dysfunction Compounds
US12/623,723 US20100069397A1 (en) 2002-08-05 2009-11-23 Sexual dysfunction compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202365A SE0202365D0 (en) 2002-08-05 2002-08-05 New formulation and use thereof

Publications (1)

Publication Number Publication Date
SE0202365D0 true SE0202365D0 (en) 2002-08-05

Family

ID=20288677

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202365A SE0202365D0 (en) 2002-08-05 2002-08-05 New formulation and use thereof

Country Status (15)

Country Link
EP (1) EP1539096A1 (en)
JP (1) JP2005539008A (en)
CN (1) CN1674866B (en)
AR (1) AR040797A1 (en)
AU (1) AU2003239038B2 (en)
BR (1) BR0313224A (en)
CA (1) CA2495527C (en)
IL (1) IL166031A0 (en)
MX (1) MXPA05000978A (en)
NZ (1) NZ537520A (en)
RU (1) RU2312665C2 (en)
SE (1) SE0202365D0 (en)
TW (1) TW200418470A (en)
WO (1) WO2004012702A1 (en)
ZA (1) ZA200500051B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232113A1 (en) 2002-07-16 2004-01-29 Bayer Ag Medicinal products containing vardenafil hydrochloride trihydrate
DE102005009241A1 (en) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Dosage forms with controlled bioavailability
DE102005009240A1 (en) 2005-03-01 2006-09-07 Bayer Healthcare Ag Dosage forms with improved pharmacokinetic properties
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
DE102010024866A1 (en) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulation for taste masking
EP3299010B1 (en) 2016-09-21 2022-11-09 LTS Lohmann Therapie-Systeme AG Oral dosage form
JP7182639B2 (en) 2018-03-01 2022-12-02 エルテーエス ローマン テラピー－ジステーメ アーゲー Oral dosage form containing theobromine-free cocoa

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755180A (en) * 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
FR2717387B1 (en) * 1994-03-17 1996-10-18 Hi Pharmtech Process for the production of chewable tablets based on troxerutin, calcium carbonate, calcium phosphate, arginine aspartate, amoxicillin arginine glutamate.
US6121276A (en) 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
ES2105970B1 (en) * 1995-08-02 1998-07-01 S A L V A T Lab Sa ORAL PHARMACEUTICAL COMPOSITION OF CIPROFLOXACINO, NON-AQUEOUS, STABLE AND WITH IMPROVED ORGANOLEPTIC CHARACTERISTICS.
CA2178021C (en) * 1996-04-19 1999-09-28 Theodore H. Stanley Tobacco substitute
AU715867B2 (en) * 1997-01-06 2000-02-10 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (en) * 1998-05-15 2000-10-14 Pfizer PHARMACEUTICAL FORMULATIONS.
JP2000095710A (en) * 1998-09-21 2000-04-04 Taisho Pharmaceut Co Ltd Oral solid preparation mixed with cacao powder
JP2000119198A (en) * 1998-10-16 2000-04-25 Eisai Co Ltd Phosphodiesterase inhibitor-containing peroral preparation hiding bitterness or the like
US6060094A (en) * 1998-10-30 2000-05-09 Nestec S.A. Method of reducing fat in fat-based coating for confectionery products
SE9803986D0 (en) * 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
US6531114B1 (en) * 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
SI20109A (en) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stable pharmaceutical formulation
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
AU779991B2 (en) 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
JP2001114668A (en) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd Chocolate preparation
CZ20022245A3 (en) 1999-12-30 2002-10-16 Tap Holdings, Inc. Oral mucous dosing forms of apomorphine
WO2002005820A1 (en) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
JP2002193839A (en) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd Cocoa pharmaceutical preparation
MXPA03007081A (en) * 2001-02-08 2004-10-15 Pharmacia Corp Rapid-onset medicament for the treatment of sexual dysfunction.
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa

Also Published As

Publication number Publication date
CN1674866B (en) 2012-09-26
EP1539096A1 (en) 2005-06-15
TW200418470A (en) 2004-10-01
NZ537520A (en) 2006-11-30
ZA200500051B (en) 2006-12-27
IL166031A0 (en) 2006-01-15
CA2495527C (en) 2008-12-30
AR040797A1 (en) 2005-04-20
MXPA05000978A (en) 2005-12-12
BR0313224A (en) 2005-07-05
WO2004012702A1 (en) 2004-02-12
AU2003239038A1 (en) 2004-02-23
CN1674866A (en) 2005-09-28
CA2495527A1 (en) 2004-02-12
RU2312665C2 (en) 2007-12-20
RU2005102835A (en) 2005-08-10
AU2003239038B2 (en) 2008-01-03
JP2005539008A (en) 2005-12-22

Similar Documents

Publication Publication Date Title
TW200510375A (en) New compounds
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
SI1478339T1 (en) Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
NO20062504L (en) Compositions and dosage forms for improved absorption
SE0103211D0 (en) New formulations and use thereof
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
ECSP045081A (en) DERIVATIVES OF 1,8-NAFTIRIDINE AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
WO2003075857A3 (en) Amino-methyl substituted tetracycline compounds
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
MY144659A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
IL174154A (en) Glp-1 derivatives, pharmaceutical compositions comprising them and their use in manufacturing medicaments
SE0100901D0 (en) New composition
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
TW200505875A (en) Novel compounds
WO2004005324A3 (en) Peptide composition for treatment of sexual dysfunction
GB0426313D0 (en) Therapeutic agents
ATE445389T1 (en) LIPOSOMAL GLUCOCORTICOIDS
MXPA03010761A (en) Pharmaceutical combinations.
SG116507A1 (en) Pharmaceutical dosage form and method of making.
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
PL366800A1 (en) Tablet comprising cetirizine and pseudoephedrine
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
MXPA05013758A (en) Pharmaceutical compositions including an antihistamine and a stimulant and use thereof.
SE0202365D0 (en) New formulation and use thereof
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine